Loading organizations...

§ Private Profile · Montréal, QC, Canada
Thrasos is a technology company.
Thrasos Therapeutics developed novel biotherapeutic drugs for treating and preventing severe organ failures, primarily focusing on kidney conditions. The company concentrated on rare kidney diseases, including myeloma cast nephropathy, and acute kidney injuries. Its approach involved discovering and advancing targeted therapies to address unmet medical needs within renal care.
Established in 2003 in Montreal, Canada, Thrasos Therapeutics was co-founded by Murty Bosukonda. The company emerged from the insight that advanced treatments were needed to protect and restore organ function, particularly in nephrology. This principle guided Thrasos’s drug development, building a pipeline targeting complex biological pathways associated with kidney damage.
Thrasos developed therapies for individuals suffering from acute and chronic kidney conditions, addressing patient populations underserved by existing treatments. The company’s mission was to pioneer innovative pharmaceutical solutions to improve outcomes for those affected by kidney disease. Thrasos envisioned a future where its interventions would enhance patient health and quality of life.
Thrasos has raised $91.0M across 3 funding rounds.
Thrasos has raised $91.0M in total across 3 funding rounds.
Thrasos has raised $91.0M in total across 3 funding rounds.
Thrasos's investors include BDC Venture Capital, Jens Eckstein, Amorchem, Apollo Health Ventures, Advanced Technology Ventures, Lumira Ventures, MP Healthcare Venture Management, Pappas Ventures, SW Co., GlaxoSmithKline, SR One, Fonds de solidarit FTQ.
Thrasos is a French greentech/deeptech company that builds an AI- and digital‑twin driven platform (NEPSYS) to optimize Cleaning‑In‑Place (CIP) and hygiene operations for food processors, reducing water, energy and chemical use while improving production uptime and product safety[3][2].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: Thrasos is a niche greentech/deeptech company applying AI and digital‑twin methods to a high‑impact operational problem in food processing; its combination of domain expertise, environmental positioning, and early commercial traction makes it a company to watch for operators seeking quick, verifiable resource savings and safer, more efficient CIP programs[3][2][4].
Thrasos has raised $91.0M across 3 funding rounds. Most recently, it raised $21.0M Series D in March 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2015 | $21M Series D | BDC Venture Capital, Jens Eckstein | AmorChem, Apollo Health Ventures, Advanced Technology Ventures, Lumira Ventures, MP Healthcare Venture Management, Pappas Ventures, SW CO. | Announced |
| Oct 25, 2012 | $35M Venture Round | Jens Eckstein | Advanced Technology Ventures, GlaxoSmithKline, Lumira Ventures, MP Healthcare Venture Management, Pappas Ventures, SW CO. | Announced |
| Oct 1, 2012 | $35M Series C | SR ONE | Apollo Health Ventures, Advanced Technology Ventures, Fonds DE Solidarit FTQ, GlaxoSmithKline, Lumira Ventures, MP Healthcare Venture Management, Pappas Ventures, SW CO. | Announced |